Cardiometabolic and molecular adaptations to 6-month intermittent fasting in middle-aged men and women with overweight: secondary outcomes of a randomized controlled trial
Barve RA, Veronese N, Bertozzi B, Tosti V, Cagigas ML, Spelta F, Cava E, Piccio L, Early DS, Head RD, Fontana L
Nature communications · 1 cita
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Alvin J. Siteman Cancer Center
- Universidad u hospital
- Georgia Clinical and Translational Science Alliance
- Organización sin fines de lucro
- Australian Youth and Health Foundation
- Gobierno
- National Institutes of Health
- Gobierno
- National Health and Medical Research Council
- Gobierno
- National Cancer Institute
- Gobierno
- National Center for Research Resources
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NCATS NIH HHS
- Gobierno
- Department of Health | National Health and Medical Research Council
- Gobierno
- Department of Health | National Health and Medical Research Council (NHMRC)
- Organización sin fines de lucro
- Australian Youth and Health Foundation.
- Gobierno
- NCI NIH HHS
- Subvenciones
- Alvin J. Siteman Cancer Center (UL1TR002345); Alvin J. Siteman Cancer Center (CA91842); National Cancer Institute (P30 CA 91842); National Health and Medical Research Council (1177797); Georgia Clinical and Translational Science Alliance (#UL1 TR002345); National Center for Advancing Translational Sciences (UL1TR002345); Alvin J. Siteman Cancer Center (#P30 CA91842); National Center for Research Resources (UL1-TR002345); National Cancer Institute (UL1 TR002345); National Cancer Institute (CA91842); National Center for Research Resources (P30 CA91842); National Institutes of Health (UL1-TR002345); National Institutes of Health (CA91842); National Cancer Institute (P30CA091842)
Según 13 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2025-12-13 · Nat Commun · vol. 16 · número 1 · pág. 11370
- Editorial
- Nature Portfolio
- Citado
- 2 citas · más que el 80% de estudios similares · 1.1× el promedio de su campo
- Referencias
- 46 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Dietary Effects on Health · Nutrition, Genetics, and Disease · Gut microbiota and health
- Palabras clave
- intermittent fasting, overweight, cardiometabolic health, body composition, lipid profile, LDL cholesterol, non-HDL cholesterol, triglycerides, plasma metabolomics, glucagon-like peptide-1, bile acid signaling, lipid metabolism, PPARα, B-cell immunity, weight loss, middle-aged adults
- MeSH
- humans, cardiovascular diseases, fasting, body composition, adult, aged, middle aged, female, male, overweight, lipid metabolism, metabolomics, intermittent fasting
11 autores
- Ruteja A. Barve🇺🇸Washington University in St. Louis
- Nicola Veronese🇮🇹University of Palermo
- Beatrice Bertozzi🇺🇸Washington University in St. Louis
- Valeria Tosti🇺🇸Washington University in St. Louis
- María Lastra Cagigas🇦🇺The University of Sydney
- Francesco Spelta🇮🇹Azienda ULSS 9 Scaligera
- Edda Cava🇮🇹Azienda Ospedaliera San Camillo-Forlanini; Carlo Forlanini Hospital
- Laura M. Piccio🇦🇺The University of Sydney
- Dayna S. Early🇺🇸Washington University in St. Louis
- Richard D. Head🇺🇸Washington University in St. Louis
- Luigi Fontana🇦🇺 · autor de correspondenciaThe University of Sydney; Royal Prince Alfred Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Intermittent fasting (IF) has gained attention as a potential intervention for cardiometabolic health, though its long-term effects remain unclear. In this randomized clinical trial, we assessed the impact of 6 months of IF on body composition, cardiovascular risk factors, and related molecular pathways in middle-aged (30-65 years) men and women with overweight (BMI 24.8-35 kg/m²). In this trial, 41 participants were randomized to either an intermittent fasting (IF) intervention or to maintain their habitual diet. The primary outcome (circulating CRP concentration) was previously reported; here, we present exploratory analyses focusing on metabolomic and transcriptomic responses. IF led to an 8% reduction in body weight, a 16% decrease in body fat, and significant improvements in lipid profile, including substantial reductions in plasma LDL-cholesterol, non-HDL-cholesterol, and triglycerides (p = 0.001). However, no significant changes were observed in other cardiometabolic risk factors. To investigate the underlying molecular mechanisms, we performed untargeted plasma metabolomics and transcriptomic analysis of colon mucosa biopsies. Significant multi-omic changes were identified, particularly in lipid metabolism, bile acid signaling, and enteroendocrine regulation. Notably, there was a downregulation of transcripts related to glucagon-like peptide 1 (GLP-1) and related enteroendocrine hormones. Correlation analysis highlighted key molecular pathways, with PPAR-α and B-cell-mediated immune processes significantly associated with changes in non-HDL cholesterol. Our findings extend the understanding of IF in humans beyond weight loss, providing key mechanistic insights to inform targeted therapies for improving cardiometabolic health. ClinicalTrials.gov NCT01964118.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.